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Summary The pre-treatment serum levels of neuron-specific enolase (NSE), phosphohexose isomerase (PHI)
and circulating immune complexes (CC) as tumour markers were compared to measurements of standard
haematology and biochemical indices in 73 patients with lung cancer, as an aid to differentiation of tumour
type, estimating disease extent, predicting response to therapy and prognosis.
Elevated NSE,12.5ngml-1, PHIk120IUP-1, CC>55mgl-1 levels were observed in 55% of cases for
NSE, 90% for PHI and 49% for CC. NSE was significantly elevated in 61% (25/41) of patients with SCLC
(P<0.005) compared to 41% (13/32) with NSCLC. CC levels were significantly raised in 72% (23/32) of
patients with NSCLC (P<0.05) compared to 32% with SCLC. The levels of NSE and PHI were not related
to tumour stage but CC was significantly raised in limited compared to extensive disease in SCLC (P<0.05).
Serum albumin was significantly lower in NSCLC compared to SCLC, and median values of alkaline
phosphatase, gamma-glutamyltranspeptidase and aminoaspartate transferase were significantly higher in
patients with extensive disease.
The pre-treatment serum values of NSE, PHI, and CC did not predict the response to therapy or prognosis
in the 73 patients with lung cancer. The most important prognostic factor was the number of abnormal
routine laboratory parameters (>4) in this group of patients.
The identification of a tumour marker which is highly
sensitive as well as specific for lung cancer, and can be
assayed by simple, reproducible and cheap techniques,
remains elusive. In addition, accurate measurement of the
tumour marker should either replace or provide further
significant information to existing staging investigations,
ideally reflecting tumour mass, correlating with prognosis
and finally be useful in monitoring therapy.
Neuron specific enolase (NSE) is a glycolytic enzyme found
in the brain, in a variety of amine precursor uptake and
decarboxylation (APUD) enzyme system containing cells, in
neuroendocrine cells, and has been identified in large amounts
in neuroendocrine tumours including small cell lung cancer
(Tapia et al., 1981). Carney et al. (1982) performed a
prospective study on 96 patients with small cell lung cancer
(SCLC). Sixty-nine per cent of all patients had elevated
serum levels of NSE, 39% of those with limited stage disease
(LD) and in 87% with extensive disease (ED). NSE levels
returned to normal in all patients who achieved complete
remission, and rose again with relapse. Failure of NSE levels
to return to normal was associated with continuous disease
activity. Similar findings have been reported in other studies
(Ariyoshi et al., 1983; Kato et al., 1983; Johnson et al., 1984;
Pahlman et al., 1984; Akoun et al., 1985; Esscher et al.,
1985). Thus measurements of NSE may provide additional
information in small cell lung cancer for staging purposes,
following disease activity, sub-clinical relapse and monitoring
therapy. These studies have shown that serum NSE levels are
less often raised in non-small cell lung cancer (NSCLC),
18% compared to 75% in SCLC, indicating that NSE may
be useful in differentiating SCLC from other lung tumours.
However, there is considerable debate on the histogenesis of
lung carcinoma and on the neuroendocrine distinction
between SCLC and NSCLC. Most tumours can be desig-
nated to a morphological type such as squamous, small cell,
adeno or large cell carcinoma. But some tumours express a
combination of these appearances in different parts of the
tumour (Willis, 1948) and also within the same tumour cell
(McDowell & Trump, 1981). The biological distinction
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between SCLC and NSCLC shows considerable overlap
(Gazdar et al., 1983), and in particular, the neural charac-
teristics as expressed in SCLC by NSE (in serum or
immunohistochemistry) appear in other non-small cell
tumours (Sidhu, 1980; Baylin et al., 1982; Dhillon et al.,
1985). Similar results for serum NSE levels in SCLC have
been obtained using different radioimmunoassays (Carney et
al., 1982; Ariyoshi et al., 1983; Johnson et al., 1984;
Pahlman et al., 1984; Akoun et al., 1985; Cooper et al.,
1985). However, in NSCLC Ariyoshi et al., 1983; Pahlman et
al., 1984; Cooper et al., 1985 commented on the high serum
NSE levels found in large cell tumours within their series of
NSCLC patients and the difficulty in distinguishing histo-
logically these tumours from SCLC. Carney (1987) observed
there was considerable heterogenicity in the expression of
biomarkers in cell lines of SCLC and NSCLC. Up to 20%
of NSCLC, in particular adenocarcinomas, have biomarkers
typical of SCLC. Thus the role of NSE as a specific tumour
marker separating SCLC from NSCLC still requires further
evaluation.
Elevation of phosphohexose isomerase (PHI) and circu-
lating immune complexes (CC) have been demonstrated in
lung cancer (West et al., 1962; Schwartz et al., 1985). PHI is
widely distributed in human tissue, and is a glycolytic
enzyme abundantly found in liver and skeletal muscle. West
et al. (1962) reported raised levels of PHI in 72% of 126
patients with lung cancer, with lower values in patients
without distant metastases and highest values in those with
hepatic metastases documented at autopsy. Schwartz et al.
(1985) stated that PHI in SCLC had the highest values in
localised disease and suggested that PHI may be a useful
marker in detecting early lung cancer. The level of circulat-
ing immune complexes in 100 patients with lung cancer
(Gropp et al., 1980) was raised in 50% of cases by measur-
ing the Clq binding activity and in 80% by column
chromatography. Patients with extensive disease had signi-
ficantly higher levels of CC than patients with limited
disease. There appeared to be a good correlation with levels
of CC and course of the disease, with the responders
showing a decrease in CC levels and an increase in the Clq
binding activity with disease recurrence. A simpler assay
(Levinson et al., 1984) for CC using absorbance nephelo-
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metry with anti-IgG as the indicator after extraction with
polyethyleneglycol of CC from serum has been shown to
correlate highly with the Clq binding test.
With the advent of simpler and cheaper techniques for
measuring CC and PHI as tumour markers, a comparative
study was therefore undertaken to compare these markers
with the established role of NSE as a biological marker in
lung cancer. We, therefore, compared the pre-treatment
serum levels of NSE, PHI and CC and compared them to
standard haematological and biochemical indices in 73
patients with lung cancer, as an aid to the differentiation of
tumour type, estimating disease extent, monitoring therapy
and as prognostic factors.
Patients and methods
Forty-one patients with small cell lung cancer (SCLC) and
32 patients with non-small cell lung cancer (NSCLC) were
studied consecutively having been referred to the Medical
Oncology Unit at Wythenshawe Hospital between August
1985 and February 1986. Histological tumour diagnosis was
based on biopsy specimens obtained at bronchoscopy, lymph
node biopsy or thoracotomy. Patients were assessed by
routine history, clinical examination, complete blood count,
biochemistry including creatinine, urea and electrolytes and
liver function tests, and chest radiography. Bone marrow
aspirate, radionuclide and ultrasound scans were performed
when there was clinical and biochemical suspicion of metas-
tatic disease. Limited disease was defined as inoperable
tumour confined to one hemithorax but including mediasti-
nal extension and ipsilateral supraclavicular lymphadeno-
pathy and disease outside these limits was classified as
extensive. Further clinical details and metastatic sites are
shown in Table I.
Serum was taken for the measurement of neuron specific
enolase (NSE), phosphohexose isomerase (PHI) and circulat-
ing immune complexes (CC) in 60 patients previously
untreated and following relapse in 10 patients after lung
resection and in 3 patients after radiotherapy. Details of lung
histology and type of treatment are summarised in Table II.
Sixty-nine patients received chemotherapy and 4 patients
received no therapy. The treatment modalities for the 69
patients who received chemotherapy consisted of varying
combinations of ifosfamide, cyclophosphamide, adriamycin,
etoposide and carboplatin. Tumour responses to chemo-
therapy and radiotherapy were judged complete (CR) when
all clinical and pathological evidence of tumour disappeared,
and partial (PR) when there was a reduction of 50% of
measurable or evaluable tumour mass for at least four
Table I Clinical details and metastatic
sites in 73 patients
Male:Female
Sites of primary tumour
R:L
Lymphadenopathy
Ipsilateral SCF
Contralateral SCF
Bilateral SCF
Axillary
Mediastinum
Pleural Effusion
Ipsilateral
Contralateral
Bone marrow
Bone (+ve scan)
Liver (+ve scan)
Brain
Soft tissue
55:18
43:30
3
1
4
1
65
9
6
3
10
19
3
weeks. Lesser degrees of tumour reduction were regarded as
no response (NR).
Determination of neuron specific enolase
Serum samples were stored at -20°C and a kit obtained
from Pharmacia, Milton Keynes, UK, was used to measure
NSE in a double antibody radioimmunoassay. The NSE in
the sample competes with a fixed amount of 1251 labelled
NSE for the binding sites of the specific antibodies. Bound
and free NSE are separated by the use of a second antibody
covalently bound to spherical particles of agarose. After
addition of the agarose antibody complex, the mixture is
centrifuged. Supernatant containing the free NSE is separ-
ated from the NSE bound to the agarose pellet by decanting.
The radioactivity in the pellet is then measured and is
inversely proportional to the quantity of NSE in the sample.
Determination ofphosphohexose isomerase
This enzyme catalyses the reversible reaction between
fructose-6-phosphate and glucose-6-phosphate. The serum
samples were stored at 4°C and the enzyme activity was
measured at 37°C by the increase in absorbance at 340nm
by the conversion of glucose-6-phosphate to 6-phospho-
gluconate in the presence of glucose-6-P-dehydrogenase and
NADP compared to a blank Tris buffer using a spectro-
photometer (Rowan, 1978).
Determination of circulating immune complexes
Serum samples were stored at - 80°C and when required CC
were extracted from each serum sample after precipitation
with polyethylene glycol. The precipitates were washed twice
and redissolved in buffer before reaction with 1251 labelled
anti-human IgG. CC levels were measured by determining
the difference in the light scatter between the test and a
blank normal serum solution using a Hyland nephelometer
PDQ instrument. The light scattered by the antigen-antibody
complexes was displayed as the % relative light scatter using
a helium neon light source of wavelength 632.8 nm (Krapf et
al., 1982; Levinson et al., 1984).
Results
Controls
For PHI the mean level in 36 laboratory staff were
73+24IU1-1. CC levels were measured in 24 laboratory staff
and 15 patients with chronic obstructive airways disease,
their mean serum levels were 25 + 13mg1-1 and
29+ 12.5mg 11 respectively. From the control results the
upper limit of normal for serum PHI and CC were estab-
lished as 2 standard deviations from the mean value, i.e.
PHI>120IUl 1, and CC>55mgl- . For NSE the upper
limit of normal was 12.5ngml-V as suggested by Pharmacia,
Sweden for their radioimmunoassay kit.
Lung cancer
There were 55 males and 18 females with a median age of 59
years (range 31 to 78 years). In the 41 patients with SCLC,
19 had limited disease and 22 extensive disease. In the 32
patients with NSCLC, 6 were limited and 26 were extensive.
We observed elevated (NSE> 12.5ngml-1, PHI > 120IUl-1,
CC>55mgl-1) levels in 54.8% of all patients for NSE,
90.3% for PHI and 49.3% for CC (Table III).
Neuron specific enolase
Forty (54.8%) of all patients had a raised serum NSE
(median 12.95ngml-1, with an overall range for all patients
of 2.3-200ngml-1. Twenty-five of the 41 patients (61%)
with SCLC had a significantly raised (P<0.0005, Mann-
Whitney Wilcoxson Rank Sum Test) serum NSE (medianTUMOUR MARKERS IN LUNG CANCER 799
Table II Lung histology and initial treatment in 73 patients
Initial treatment
Surgery
Lung histology n CHEM XRT Surgery and XRT No therapy
SCLC 41 36 1 2 1
SQ moderate 8 4 2 1 -
SQ poor - - -1
Large 5 2 - 2 -
AD moderate 7 6 - -1
AD poor 9 5 - 2 2
Malignant carcinoid 1 1
Adenoid cystic CA 1 1
CHEM=Chemotherapy; XRT= Radiotherapy.
Table III Serum neuron specific enolase (ngml-1), phosphohexose isomerase (IU-1) and circulating immune complex (mgl-) and type and
stage of lung tumour
NSE (ngml- ) PHI (IU -1) CC(mgl- 1)
No. (%) NSE
n >12.5ngml- 1
73 40 (55)
41 25 (61)
19 12 (63)
22 13 (59)
32 13 (41)
6 2(33)
26 11(42)
Median
(range)
164
(47-1,200)
156.6
(47-1,200)
148
(109-327)
171.5
(47-1,200)
173.5
(109-514)
180.5
(125-280)
156
(109-514)
No. (%) PHI
n J120IUlI1
72 65 (90)
40
18
22
33 (82)
15 (83)
18 (82)
32 29 (91)
6 6 (100)
26 23 (89)
Median
(range)
50.5
(2-164)
45.8
(2-154)
52b
(2-154)
41
(4-102)
74.5c
(4-164)
46
(10-164)
75.5
(4-124)
n
73
No. (%)CC
>55mgl-
36 (49)
41 13 (32)
19 9 (47)
22 4 (18)
32 23 (72)
6 3(50)
26 20 (77)
aP<0.005; P<0.05; cP<0.05.
P values=Mann-Whitney Wilcoxson Rank Sum Two-Tailed Tests.
24.4 ngml -1, range 3.4 to 200 ngml -1). For patients with
SCLC and NSCLC there was no significant difference in the
levels of NSE whether the tumour stage was limited or
extensive (Figure 1 and Table III).
Phosphohexose isomerase
Sixty-five (90.3%) patients had an elevated serum PHI
(median 164 IU 1- 1, range 47-1,200 IU 1- ). Thirty-three
patients with SCLC (82.5%) had a raised serum PHI
(median 156.61U1- 1, range 47-1,200IU1-V) and in 29/32
(90.6%) with NSCLC were elevated (median 173.5 IU 1- 1,
range 109-514IU1 1). There was no significant difference in
the values of PHI in SCLC and NSCLC whether the patients
had limited or extensive disease (Figure 2).
Circulating immune complexes
Thirty-six (49.3%) of all patients were found to have
increased levels of CC (median 50.5 mg 1 ', range 2-
164mg1- 1). CC levels were significantly elevated (P<0.05
Mann-Whitney Wilcoxson Two-Tailed-Test) in 23 out of the
32 patients with NSCLC (71.9%), median 74.5mg -1,
(range 4-164), compared to 31.7% in the SCLC group
(13/41), median 45.75 mgl-1 (range 2-154mg - 1) (Table III).
In forty-one patients with SCLC, (Table III), 19 patients
with limited disease had significantly elevated (P<0.05) CC
levels (median value 52mgl-1, range 2-154mgl-1) com-
pared to 22 patients with extensive disease (median value
41 mgl-', range 4-102mgl-1). There was no significant
difference in the levels of CC between those patients with
limited and extensive disease in NSCLC (Figure 3).
Liver function tests
For SCLC and NSCLC there was no significant difference in
alkaline phosphatase (AP), gamma-aminotranspeptidase
(GGT), aspartate-aminotransferase (AST) and lactic
dehydrogenase (LDH) values as shown in Table IV. How-
ever, in those patients with SCLC and extensive disease AP
(median 145.5 IU1-1), GGT (median 83.5 IU 1-l) and AST
(median 35 IU -1) were increased significantly compared to
those with limited disease: AP, median 96IU1-l (P<0.01),
GGT, median 361U1 (P<0.01), and AST, median
23.4IU1 (P<0.05) using Mann-Whitney Wilcoxson Rank
Sum Tests.
In NSCLC serum albumin was significantly lower median
34.7 g 1- 1 compared to SCLC, median 40 g1- 1 (P<0.005),
(Table IV).
Response
Fourteen or 21% of patients were classified as a complete
response when assessed clinically and radiologically one
month after the end of treatment. Twenty-six patients or
38% were partial responders. Twenty-nine patients or 41%
were non-responders. The proportion of patients with SCLC
achieving a complete or partial response was 77% compared
with 33% in the NSCLC group. Further statistical analysis
of the response to therapy in the 69 evaluable lung cancer
patients did not include the histological type, stage of lung
tumour in relation to the value of tumour markers nor
standard haematological and biochemical indices because of
the small numbers involved.
The patients response to therapy was not significantly
Patients
Total
(n =73)
SCLC
(n=41)
Limited
(n = 19)
Extensive
(n =22)
NSCLC
(n = 32)
Limited
(n=6)
Extensive
(n =26)
Median
(range)
12.95
(2.3-200)
24.4a
(3.4-200)
14
(2.8-108)
45.8
(3.4-200)
10.8
(2.3-60)
7.9
(2.3-28.6)
10.8
(6-60)800 S.A. GOMM et al.
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Figure The median and distribution of serum NSE levels with
the type and stage of lung tumour.
associated with the pre-treatment serum values of NSE
(X2=0.58, P>0.7), PHI (Fisher's exact test, P>0.08) or CC
levels (X2=2.5, P>0.2) as shown in Table V. A greater
proportion of patients who had an elevated AP
(> 140IUI1) and GGT (>50IUl-1), 65% and 82% respec-
tively, were non-responders, and a greater proportion who
were complete or partial responders were found to have
serum levels of AP, 79% and 65% respectively, and GGT
54% and 56% within the normal range, and 93% and 85%
respectively with a serum albumin >35gl-1. These associa-
tions were significant: AP, X2=9.211, P<0.01; GGT,
x2=8.896, P<0.02 and serum albumin, Fisher's exact test,
P<0.03 (Table V).
The laboratory variables of haemoglobin, white cell count,
sedimentation rate, platelet count, urea, creatinine, sodium,
potassium, bicarbonate, chloride, aspartate aminotransferase,
lactic dehydrogenase, total protein and calcium were not
significant predictive factors for patients response to therapy.
However if patients had seven or more abnormal indices a
significantly greater proportion (66%) were non-responders.
A greater proportion were complete responders (86%) and
partial responders (62%) when the number of abnormal
indices was less than 7 (X2 = 10.72, P<0.005, Table VI).
Survival
The overall median survival for the 73 patients with lung
cancer was 10 months (range 1 to 14+) months. The median
survival for the 14 patients achieving a complete response
was 11 months. The median survival for partial responders
was 8 months (range 1 to 14+) and 2 months (range <1 to
9) for non-responders. No patients were excluded from the
survival analysis.
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Figure 2 The median and distribution of serum PHI levels with
the type and stage of lung tumour.
Survival curves were calculated following the method of
Kaplan & Meier (1958) and significance tests based on log-
rank analysis (Kaplan et al., 1958; Peto et al., 1977). To
determine the most significant pre-treatment variables which
were related to survival, Cox's proportional hazard model
(1972) was used. A forward stepwise progression procedure
being employed to determine combinations of patients
characteristics which were important for predicting survival.
A significance level of 5% was set as the limit for inclusion
in the model.
The effect on survival of each of 32 pre-treatment vari-
ables was assessed and the results of the first step analysis
are summarised in Table VII. Age, sex, white cell count, and
several other variables including serum levels of NSE, PHI,
and CC were not found to be significantly related to
prognosis (group A). Seven variables including alkaline phos-
phatase, haemoglobin, AST, tumour type and lung metasta-
sis were associated with a significance of <0.05 but greater
than 0.01 (group B). The remaining five variables all showed
a P value <0.01 (group C) and consisted of LDH, serum
albumin, tumour stage, liver metastasis and the continuous
variable of four or more abnormal haematological and
biochemical indices. At the end of multiple regression analy-
sis, only 2 variables were still significantly related to survival.
These variables were selected at each step together with their
significance value and were each independently related to
survival: >4 abnormal indices, P<0.000004 and liver metas-
tasis, P<0.008. The survival curves for each of these vari-
ables are shown in Figure 4.
Discussion
We observed elevated levels of serum NSE in 55% of all
cases, 90% for PHI and 49% for CC in 73 patients with
lung cancer. Previous studies (Carney et al., 1982; Kato et
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Figure 3 The median and distribution of circulating immune
complexes with the type and stage of lung tumour.
al., 1983; Ariyoshi et al., 1983; Pahlman et al., 1984; Akoun
et al., 1985; Esscher et al., 1985; Cooper et al., 1985) have
demonstrated significantly higher levels of NSE in SCLC
compared to other forms of lung cancer, with significant
elevation of serum levels of NSE in patients with extensive
compared to limited disease in SCLC. These observations
were confirmed in our study, however, the median serum
values of NSE in those patients with SCLC and extensive
disease were higher than in limited disease but did not
achieve statistical significance. Elevated serum levels of NSE
(>12.5ngml1) were observed in 41% (13/32) in our
patients with NSCLC compared to 18% (45/254) in previous
studies (Ariyoshi et al., 1983; Pahlman et al., 1984; Akoun et
al., 1985; Cooper et al., 1985; Esscher et al., 1985). Interpre-
tation of raised serum NSE levels in SCLC and NSCLC
depend upon accurate histological classification, the neuro-
endocrine properties expressed by the tumour, and the upper
limit of normal for NSE set for by the type of radioimmuno-
assay used. Further comparison of serum NSE values in
NSCLC show that 77% were raised in the range 13-
25ngml-1 in our study and in 69% in previous studies, with
23% and 31% respectively >25ngml-'. The use of a more
discriminative upper limit for NSE of >25 ngml- will
result in a decreased sensitivity and a higher specificity.
Overall NSE as a tumour marker in lung cancer is poten-
tially useful in SCLC in assessing disease extent, monitoring
therapy and sub-clinical relapse, however, the pretreatment
values were normal in 41% of our SCLC patients and in up
to 30% in previous studies. Further clinical studies are
required in larger numbers of patients with NSCLC with
regard to neuroendocrine behaviour and subsequent tumour
response to therapy.
The median values of serum PHI in both SCLC and
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Table V The relationship of response to therapy and the number and percentage of normal and abnormal
values for tumour markers, alkaline phosphatase, gamma GT and serum albumin in 69 treated patients with
lung cancer
NSE (ngml-)
Normal >12.5
8 (57%) 6 (43%)
13 (50%) 13 (50%)
13 (45%) 16 (55%)
x2=0.58, P>0.7
AP (IUI-1)
Normal >140
11 (79%) 3 (21%)
17 (65%) 9 (35%)
10 (35%) 19 (65%)
X2=9.211, P<0.01
PHI (IU -1)
Normal
3 (21%)
5 (20%)
1 (3.5%)
CC (mgl-1)
> 120 Normal
11 (79%)
20 (80%)
28 (96.5%)
Fisher's exact test,
P>0.08
GGT (IUl-1)
Normal >50
7 (54%) 6 (46%)
14 (56%) 11 (44%)
5 (18%) 22 (82%)
x2=8.896, P<0.02
>.55
9 (64%) 5 (36%)
15 (58%) 11 (42%)
12 (41%) 17 (59%)
x2=2.5, P>0.2
Albumin (gl-1)
Normal <35
13 (93%)
22 (85%)
17 (59%)
1 (7%)
4 (15%)
12 (41%)
Fisher's exact test,
P<0.03
Table VI The number of abnormal haematologi-
cal and biochemical indices and response to
therapy
Number of abnormal
haematological and
biochemical indices
Response
CR
PR
NR
I to 6
12 (86%)
16 (62%)
10 (34%)
2 (14%)
10 (38%)
19 (66%)
x2 =10.72, P<0.005.
NSCLC were increased at 156.61Ul 1 and 173.51Ul1
respectively, but measurement of the glycolytic enzyme did
not differentiate between the type or stage of lung cancer. In
an earlier report (West et al., 1962) 72% of 126 patients with
lung cancer had elevated serum levels of PHI with higher
values occurring in those with distant metastasis. Bodansky
(1954) had previously observed a close correlation of serum
PHI and the presence of bone and hepatic metastases in
carcinoma breast. Conflicting views (Schwartz et al., 1985;
d'Eril et al., 1986) have been expressed on the specificity and
sensitivity of PHI in lung cancer. Schwartz et al. (1985)
stated that in 77 patients with lung cancer PHI exhibited a
high sensitivity in detecting lung cancer with good specificity
for normal subjects and in patients with benign lung
tumours, but was less specific in benign respiratory diseases.
Forty-four patients with SCLC had the highest values for
PHI and the levels in those patients with localised disease
were not significantly different from patients with advanced
disease, and suggested that PHI may be a useful marker in
the early detection of lung cancer. In contrast, d'Eril et al.
(1986) stated that PHI in lung cancer had only fair sensiti-
vity and a very low specificity, in that the mean values of
PHI were similar to other neoplasms and other non-
neoplastic respiratory diseases, and there was no significant
difference in the mean values between early and metastatic
lung cancer. Our study similarly showed that PHI could not
differentiate the type of lung tumour or provide additional
information for staging purposes.
In the present study, serum levels for CC were signi-
ficantly higher in NSCLC, compared to SCLC. Gropp et al.
(1980) reported that the incidence of CC using the %
inhibition of Clq binding uptake was similar in the different
histological types of lung cancer in 100 patients. Their study
also demonstrated higher levels of CC in 75% of patients
with metastases in contrast to only 25% in those with
localised disease. Similar observations have been made in
acute leukaemia, lymphoma and other solid tumours
(Heimer & Klevi, 1976; Theofilopoulus et al., 1976; Teshima
Table VII Pre-treatment variables
Group A (P>0.05)
Age
Sex
White cell count
Platelets
Sodium
Potassium
Chloride
Calcium
Bicarbonate
Immune complexes
NSE
PHI
Site of tumour in lung
Interval first symptom to diagnosis
Interval diagnosis to treatment
Mediastinal nodes
Other metastasis
Bone metastasis
Lymph nodes
Soft tissue metastasis
Lung pathology
Lung metastasis
Haemoglobin
Urea
Alkaline phosphatase
Asp aminotransferase
Gamma GT
Group C(P <0.01)
(0.0403)
(0.0341)
(0.0351)
(0.0467)
(0.0168)
(0.0422)
(0.0482)
LDH
Albumin
Stage
aLiver metastasis
a4 Abnormal
indices
(0.0067)
(0.0017)
(0.0036)
(0.00002)
(0.000001)
aSignificant variables in final model: bold letters.
Note: (i) ALT, ESR, bone marrow metastasis were not included as their numbers were too few. (ii) Serum protein excluded as all
measurements were within the normal range.
Response
CR
PR
NR
CR
PR
NR
Group B (0.01 >P<0.05)TUMOUR MARKERS IN LUNG CANCER 803
100
- S 4 Abnormal indices
- -> 4 Abnormal indices
Liver metastasis
80
60 l
40 L
LX
20
0
6 12 18 24
Months
Figure 4 Survival curves with abnormal haematology and bio-
chemical indices and the presence of hepatic metastases in 73
patients with lung cancer.
et al., 1977). In contrast, we have not shown significantly
higher levels of CC in patients with lung cancer and
extensive disease. The assay for CC employed in this study
has been previously shown (Levinson et al., 1984) to corre-
late highly with Clq binding technique, and therefore tech-
nique seems unlikely to explain the differing results.
It was evident that in the 41 patients with SCLC, the
median values of AP, GGT and AST were significantly
elevated in those patients with extensive disease compared to
those with limited disease. The levels of GGT, alkaline
phosphatase and oxidative liver enzymes have been observed
previously to rise at a relatively late stage of tumour
dissemination (West et al., 1962; Neville & Cooper, 1976).
The levels of NSE, PHI and CC did not correlate with the
bulk of disease (i.e. the number of metastatic sites involved).
The use of other tumour markers (ACTH, calcitonin and
CEA) may allow a better correlation with the extent of
disease (Havemann et al., 1985). A recent study by Cooper
et al. (1987) in SCLC showed that NSE was a more sensitive
indicator of disease activity and monitoring therapy com-
pared to CEA and acute phase proteins.
The pre-treatment serum values of the tumour markers
NSE, PHI and CC did not predict the patients' response to
therapy and were not significant prognostic factors. A
greater proportion of patients with an elevated AP or GGT
were non-responders, and a greater proportion of patients
who went into complete remission or partial response had
serum levels of AP or GGT within their normal range or a
serum albumin >35gl-1. Other individual haematology or
biochemical indices at presentation were not predictive
factors for response to therapy in the 69 evaluable patients
with lung cancer. However, the presence of more than 7
abnormal indices was significantly associated with a greater
proportion of non-responders, and conversely a greater
proportion were complete responders and partial responders
when the number of abnormal indices was less than 7.
Only two out of 32 pre-treatment variables were signi-
ficantly related to prognosis after evaluation in a multiple
regression analysis, although other variables, e.g., tumour
stage, serum albumin, alkaline phosphatase, etc., were signi-
ficant on univariant analyses, but the presence of more than
four abnormal indices and liver metastasis were the only
important, independent variables. Once they had been
included in the model no other variable contained any
significant additional prognostic information.
In our study, the presence of 4 abnormal indices was the
most important prognostic factor after evaluation in a
multiple regression analysis and it was not possible to
identify which combination of individual haematological and
biochemical variables specifically affected survival due to the
small numbers involved. However, as in previous studies
(Cohen et al., 1981; Souhami et al., 1985; Cerny et al., 1987)
the use of simple laboratory parameters provide as much
information for prognosis as the other staging procedures of
scans, bone marrow, etc. Cohen et al. (1981) identified a
high plasma albumin and haemoglobin as the most influen-
tial prognostic factors in 56 patients with SCLC. Souhami et
al. (1985) analysed 371 patients with SCLC and reported
Karnofsky performance score, serum albumin, sodium, alka-
line phosphatase and disease extent as independently signi-
ficantly related to survival. Similarly, our own group (Cerny
et al., 1987) found lactic dehydrogenase, sodium, Karnofsky
performance score, alkaline phosphatase, tumour stage and
bicarbonate, as important prognostic factors in 407 patients
with SCLC. The presence of liver metastasis was the next
most important independent pre-treatment variable in our
present study (P<0.008). Ihde et al. (1981) stated that the
median survival progressively worsened with increasing
number of metastatic sites, and that metastasis to liver and
brain significantly shortened survival in 106 patients with
SCLC treated with chemotherapy. Similar observations on
the presence of hepatic metastasis on survival have been
made in both treated and untreated lung cancer patients
(Zelen, 1973; Lanzotti et al., 1977).
Earlier studies using univariate analysis reported perfor-
mance score and extent of disease as the most important
prognostic factors in lung cancer (for review, Stanley, 1985),
but included only a few of the plethora of patient factors
which may provide pertinent information in the assessment
of survival. More recent studies (Cohen et al., 1981; Sou-
hami et al., 1985; Cerny et al., 1987) have shown that the
inclusion of standard haematological and biochemical indices
and clinical features are required in a multiple regression
analysis for predicting survival in lung cancer. The present
study has shown that NSE, PHI and CC as pre-treatment
biological markers did not provide any additional infor-
mation to existing staging investigations nor predict the
response to therapy or the outcome in this group of 73
patients with lung cancer. The number of abnormal routine
laboratory parameters was the most important prognostic
factor.
We would like to thank Miss Gail Smart for her help in preparing
and typing the manuscript.
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